Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

Georgina Long, BSc, PhD, MBBS, FRACP, FAHMS, The University of Sydney, Sydney, Australia, discusses the results of the NeoPeLe trial (NCT04207086), a Phase II trial of neoadjuvant pembrolizumab combined with lenvatinib in resectable stage III melanoma. A high pathological complete response and pathological response rate was observed with neoadjuvant pembrolizumab and lenvatinib, higher than previous studies of PD1 alone. The trial and translational investigations are ongoing, and relapse-free survival and overall survival data will be collected. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.